NASDAQ$OBIO
Orchestra Biomed Holdings In · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Orchestra BioMed Holdings, Inc. reports Q4 2024 earnings with a net loss of $61.0 million and total revenue of $2.638 million.
Orchestra BioMed Holdings, Inc. reported a net loss of $61.0 million for the year ended December 31, 2024, an increase from the $49.1 million net loss in the previous year. Total revenue for the year was $2.638 million, a slight decrease from $2.760 million in 2023. The company continues to incur substantial expenses, particularly in research and development, and anticipates needing additional funding to support its operations and product commercialization goals.
- The company reported a net loss of $61.0 million for the year ended December 31, 2024, compared to $49.1 million in the previous year.
- Total revenue for the year ended December 31, 2024, was $2.638 million, a decrease of 4% from $2.760 million in 2023.
- Research and development expenses increased by 27% to $42.804 million in 2024, driven by ongoing clinical studies and program costs.
- The company's cash and cash equivalents decreased to $22.261 million at year-end 2024, raising substantial doubt about its ability to continue as a going concern without additional funding.
Headline financials
Revenue & EPS history
Orchestra Biomed · Revenue · Quarterly
$2.64M
Revenue by segment
Orchestra Biomed · $2.64M total across 2 segments · Q4 2024
- Partnership revenue$2.01M-4.8%76.0%
- Product revenue$633K-3.2%24.0%
Forward guidance
Orchestra BioMed Holdings, Inc. anticipates continued operating losses and significant expenses related to clinical studies and product commercialization. The company expects to need substantial additional funding to meet its operational and strategic objectives.
Tailwinds
- Continued focus on advancing flagship product candidates, AVIM therapy and Virtue SAB, through late-stage clinical research and regulatory approvals.
- Strategic collaborations with leading medical device companies like Medtronic and Terumo to drive global commercialization.
- Potential for AVIM therapy to significantly increase the commercial value of the global pacemaker device market.
- Virtue SAB has Breakthrough Device designation by the FDA for multiple indications, potentially accelerating regulatory pathways.
- Ongoing efforts to expand the product pipeline through collaborations, acquisitions, and intellectual property licensing.
Headwinds
- Substantial doubt about the company's ability to continue as a going concern without additional funding.
- Risk of delays or failures in clinical studies, which are lengthy, expensive, and have uncertain outcomes.
- Potential for product candidates to not achieve or maintain market acceptance even if approved.
- High dependency on partners for successful marketing and sales, with no assurance of successful partnerships.
- Exposure to geopolitical risks and supply chain disruptions, particularly from foreign suppliers, which could impact operations and costs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2024
+4.3%
Avg return
Earnings day
+2.2%
Avg return
5 days after
+5.7%
Avg return
30 days after
63%
12 / 19 earnings
Positive
+30.5%
Q4 2022
Best reaction
-6.0%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.8% | -4.9% | +4.1% | |
| Q4 2025 | +4.7% | +4.9% | -2.0% | |
| Q3 2025 | +4.6% | +12.4% | +9.1% | |
| Q2 2025 | -2.6% | +1.8% | +4.0% | |
| Q1 2025 | +0.3% | -5.9% | +16.6% | |
| Q4 2024 | -6.0% | -4.4% | -11.1% | |
| Q3 2024 | -1.0% | -4.7% | -12.9% | |
| Q2 2024 | -3.7% | +3.7% | -8.1% | |
| Q1 2024 | +10.4% | +10.6% | +68.6% | |
| Q4 2023 | +0.2% | -5.9% | -16.5% | |
| Q3 2023 | +29.6% | +28.8% | +58.3% | |
| Q2 2023 | +5.3% | -0.5% | +9.2% | |
| Q1 2023 | +2.5% | +15.3% | -16.8% | |
| Q4 2022 | +30.5% | -12.1% | -1.6% | |
| Q3 2022 | +0.3% | -0.4% | +0.1% | |
| Q2 2022 | +0.0% | +0.1% | +0.2% | |
| Q4 2021 | +0.0% | +0.2% | +0.4% | |
| Q1 2022 | +0.0% | +0.2% | +0.4% | |
| Q1 2021 | +3.7% | +1.8% | +6.2% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro